Curriculum Vitae

PROF. DR. ANITA ZARINA BINTI BUSTAM @ MAINUDIN

Professor
  • Dean Office
    Faculty of Medicine
  • +603-79492185

AREAS OF EXPERTISE

  • CLINICAL ONCOLOGY WHICH COVERS ALL ASPECTS OF NON-SURGICAL TREATMENT MODALITIES FOR CANCER PATIENTS IN PARTICULAR WITH RADIOTHERAPY, CYTOTOXICS, HORMONES AND BIOLOGICS. TUMOUR SITE SPECIALIZATION INCLUDES BREAST,LUNG, BRAIN, LYMPHOPROLIFERATIVE TISSUE, PAEDIATRICS AND SKIN.

ACADEMIC QUALIFICATION

  • FRCR(UK)(2000), (Radiotheraphy & Oncology)
    Royal College of Radiologist, London
  • MBBS(CARDIFF)(1992), (Medicine and Surgery)
    University of Wales College of Medicine, Cardiff

ADMINISTRATIVE DUTIES

  • AJK Penulisan Kurikulum Nasional Sarjana Perubatan Klinikal bagi bidang Onkologi Klinikal
    01 Jan 2016 - present (National)
  • Ahli Jawatankuasa PPGP
    01 Oct 2013 - present (Faculty)
  • Postgraduate Curriculum Working Group
    23 Sep 2014 - present (Faculty)
  • Clinical Oncology Specialty Committee member
    01 Jan 2021 - 31 Dec 2021 (National)
  • National curriculum writing group member
    01 Jan 2021 - 31 Dec 2021 (National)
  • National Project Coordinator
    30 Jan 2018 - 31 Dec 2021 (International)
  • JKKF Committee member
    06 Apr 2017 - 05 Apr 2020 (University Malaya)
  • HRPP Committee member
    02 May 2017 - 01 May 2019 (Faculty)
  • Programme Coordinator
    02 Sep 2016 - 01 Sep 2017 (University Malaya)
  • Quality Manager
    04 Jul 2016 - 03 Jul 2017 (University Malaya)
  • Programme Coordinator
    01 Sep 2014 - 01 Sep 2016 (Faculty)
  • Quality Manager
    01 Jul 2014 - 01 Jul 2016 (Faculty)
  • Head
    01 Sep 2012 - 31 Aug 2013 (Universiti Malaya)
  • Head Coordinator
    01 Oct 2002 - 31 Aug 2013 (Faculty)
  • Head of Department
    01 Aug 2000 - 31 Aug 2013 (Faculty)
  • National Project Coordinator for IAEA project RAS6040
    01 Jan 2005 - 31 Dec 2009 (National)

MEMBERSHIPS

  • FARO, ELECTED COUNCIL MEMBER
    Since 2014 (International)
  • SEAROG, EXCO MEMBER
    Since 2014 (International)
  • NPC SOCIETY OF MALAYSIA, LIFE MEMBERSHIP
    Since 2011 (National)
  • MALAYSIAN ONCOLOGICAL SOCIETY, COMMITTEE
    Since 2001 (National)
  • FARO, COUNCIL MEMBER
    2019 to 2019 (International)
  • SEAROG, ADVISOR
    2019 to 2019 (International)

AWARD AND STEWARDSHIP

  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2020 (University)
  • Certifcate of Appreciation
    FARO, 2019 (International)
  • Certificate of appreciation
    Faculty of Medicine,UM, 2019 (University)
  • Appreciation letter
    FARO 2018 organising committee, 2018 (International)
  • Live surgery IORT workshop
    College of Surgeons and Academy of Medicine Malaysia, 2017 (National)
  • Certificate of appreciation
    UMMC, 2017 (National)
  • Letter of appreciation
    Universiti Malaya, 2016 (University)
  • Certificate of appreciation
    MASPHO, 2016 (National)
  • Certificate of Appreciation
    Malaysian Psychiatric Association, 2016 (National)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2014 (University)
  • Appreciation
    UMMC, 2014 (Community)
  • KHIDMAT SETIA 20 AWARD
    , 2013
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2012 (University)
  • Appreciation
    IAEA, 2012 (National)
  • Anugerah Khidmat Cemerlang
    Universiti Malaya, 2012 (University)
  • Eskpo Penyelidikan, Rekacipta dan Inovasi UM 2009
    Universiti Malaya, 2009 (University)
  • Anugerah Khidmat Cemerlang
    Universiti Malaya, 2009 (University)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2009 (University)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2007 (University)
  • Appreciation
    Dept of Biomedical Imaging, UMMC, 2007 (University)
  • Appreciation
    National cancer registry, 2007 (National)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2006 (University)
  • Anugerah Khidmat Cemerlang
    Universiti Malaya, 2006 (University)
  • Bronze medal for the category of Fundamental Research: Oxidative stress biomarkers in breast cancer. Eskpo Penyelidikan, Rekacipta dan Inovasi 2006, 18-20 Julai
    Universiti Malaya, 2006 (University)
  • Gold medal for the category of Invention & Innovation sempena Eskpo Penyelidikan, Rekacipta dan Inovasi 2005, 14-17 Jun. Oral Cancer Database Software- Real and Virtual Tumor Bank System (OCDS/RVTBS)- An Aid for Multicenter Studies.
    Universiti Malaya, 2005 (University)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2005 (University)
  • Appreciation
    ministry of health, 2004 (National)
  • Appreciation
    MITC, UMMC, 2004 (University)
  • Appreciation
    MOH, 2004 (National)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2003 (University)
  • Appreciation
    National cancer registry, 2003 (National)
  • Anugerah Khidmat Cemerlang
    Universiti Malaya, 2003 (University)
  • Anugerah Khidmat Cemerlang
    Universiti Malaya, 2002 (University)
  • Anugerah Khidmat Cemerlang
    Universiti Malaya, 2001 (University)

PUBLICATIONS

Article in Journal
WoS
  1. See, M. H., Ung, N. M., Wong, J. H. D., Zaili, Z., Malik, R. A., Bustam, A. Z., . . . Taib, N. A. M. (2021). Evaluation of skin dose and skin toxicity in patients undergoing intraoperative radiotherapy for early breast cancer. Journal of Applied Clinical Medical Physics, 22(8), 139-147. doi: 10.1002/acm2.13338
  2. Kong, Y. C., Bhoo-Pathy, N., ORorke, M., Subramaniam, S., Bhoo-Pathy, N. T., See, M. H., . . . Yip, C. H. (2020). The association between methods of biopsy and survival following breast cancer A hospital registry based cohort study. Medicine, 99(6), 7. doi: 10.1097/md.0000000000019093
  3. Ghani, W. M. N., Ramanathan, A., Prime, S. S., Yang, Y. H., Razak, I. A., Rahman, Z. A. A., . . . Zain, R. B. Survival of Oral Cancer Patients in Different Ethnicities. Cancer Investigation, 13. doi:10.1080/07357907.2019.1635614
  4. Iwata, H., Masuda, N., Kim, S. B., Inoue, K., Rai, Y., Fujita, T., . . . Chan, A. (2019). Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncology, 15(21), 2489-2501. doi:10.2217/fon-2019-0143
Others
  1. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early-stage HER2-positive breast cancer
  2. Survival of oral cancer patients in different ethnicity
  3. MARNIZA SAAD, Flora Li Tze Chong, Anita Zarina Bustam, Gwo Fuang Ho, Rozita Abdul Malik, Wan Zamaniah Wan Ishak, Vincent Chee Ee Phua, Mastura Md Yusof, Ning Yi Yap, Adlinda Alip. The efficacy and tolerability of scalp cooling in preventing chemotherapy induced alopecia in patients with breast cancer receiving anthracycline and taxane based chemotherapy in an Asian setting. Ind Journal of Cancer, 2018;157-161.
  4. Syadwa Abdul Shukor, Anita Zarina Bustam, Palliative radiotherapy for advanced Cancer: Are we giving it to the right patient at the right time?Med J Malaysia Vol 73 No 4 August 2018
  5. Miguel Martin, MD et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology Nov 13, 2017
  6. Moradi, F., Ung, N.M., Khandaker, M.U., Mahdiraji, G.A., SAAD, M., Malik, R.A., Bustam, A.Z., Zaili, Z. and Bradley, D.A.,(2017). Monte Carlo skin dose simulation in intraoperative radiotherapy of breast cancer using spherical applicators. Physics in medicine and biology. 62, 6550-66.
  7. Rosenblatt, E.,Prajogi, G. B., Barton, M., Fidarova, E.,Eriksen, J. G., Haffty, B., Millar, B. A.,Bustam,A., Zubizarreta, E., & Abdel-Wahab,M. (2017). Need for Competency-Based Radiation Oncology Education in Developing Countries. Creative Education, 8, 66-80.
  8. The challenges of treating childhood medulloblastoma in a country with limited resources: 20 years experience at a single tertiary centre in Malaysia. Journal of Global Oncology, 2016
  9. Chandramathi S, Suresh K, Anita ZB, Rokiah P, Kuppusamy UR. Urinary Advanced Oxidation Protein Product (AOPP): A Potential Oxidation Damage Marker for Cancer . West Indian Medical Journal, In press.
  10. Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, MARNIZA SAAD, Adlinda Alip, Wan Zamaniah Wan Ishak. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
  11. Yahaya NA1, Subramanian P, Bustam AZ, Taib NA.2015.Symptom Experiences and Coping Strategies among Multi- ethnic Solid Tumor Patients Undergoing Chemotherapy in Malaysia.Asian Pac J Cancer Prev 16(2):723-30.
  12. Nor Zuraida Zainal, Norley Shuib, Anita Zarina Bustam, Zuraida Ahmad Sabki, Ng Chong Guan. 2013. Reliability and Validity of the Malay Version of the Breast-Impact of Treatment Scale (MVBITS) in Breast Cancer Women undergoing Chemotherapy. Asian Pacific J Cancer Prev, 14 (1), 463-468
  13. Zain RB, Athirajan V, Ghani WM, Razak IA, Raja Latifah RJ, Ismail SM, Sallam AA, Bustam AZ, Rahman ZA, Hussien A, Talib N, Cheong SC, Jallaludin A.2013 An oral cancer biobank initiative: a platform for multidisciplinary research in a developing country. Cell Tissue Bank. 14(1):45-52
  14. Chee Ee Phua, Anita Zarina Bustam, Mastura Md Yusof, MARNIZA SAAD, Cheng-Har Yip, Nor Aishah Taib and Char Hong Ng. 2012 Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC). Journal of Cancer Therepeutics & Research 1: 13
  15. Phua Chee Ee, Anita Zarina Bustam,Mastura Md Yusof, MARNIZA SAAD,Yip Cheng-Har, Nor Aishah Taib, Ng Char Hong, Teh Yew Ching 2012. Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting. Asia Pacific Journal of Cancer Prevention; 13(9), 4623-4626.
  16. Chandramathi S,Suresh K,Anita ZB,Kuppusamy UR (2011). Infection of Blastocystis hominis and microsporidia: are they opportunistic? Trans. R. Soc. Trop. Med. Hyg.
  17. Chong HY, Taib NA, Rampal S, Saad M, Bustam AZ, Yip CH. Treatment options for locally advanced breast cancer experience in an Asian Tertiery Hospital Asian Pac J of Cancer Prev 2010;11(4):913-7.
  18. Choong LP, Taib NA, Rampal S, SAAD M, Bustam AZ, Yip CH. High tumour stage and margin clearance are still important prognostic factors for postmastectomy locoregional recurrence in Malaysia. Asian Pac J Cancer Prev 2010;11(4):1409-16.
  19. Hoong-Yin Chong, Nur Aishah Taib, Sanjay Rampal, Marniza Saad, Anita Zarina Bustam, Cheng-Har Yip. Treatment options for locally advanced breast cancer - experience in an Asian tertiary hospital. APJCP, 11:2010;1-5.
  20. Lau Peng Choong, Nur Aishah Mohd Taib, Sanjay Rampal, Marniza Saad, Anita Zarina Bustam, Yip Cheng Har; High Tumour Stage and Margin Clearance are still important prognostic factors for post-mastectomy locoregional recurrence in Malaysia; Asian Pacific Journal for Cancer Prevention,11,1409-1416 Dec 2010
  21. Phua CE, Bustam AZ, Yip CH, Taib NA. 2010. Prognostic factors for elderly breast cancer patients in University Malaya Medical Centre, Malaysia. Asian Pac J Cancer Prev. 11(5):1205-11.
  22. Prognostic Factors for Elderly Breast Cancer Patients in University Malaya Medical Centre, Malaysia CE Phua1*, AZ Bustam2, Cheng-Har Yip3, Nor Aishah Taib3 2010 Asian Pacific J Cancer Prev, 11, 1205-1211
  23. Seriramalu R, Pang W, Jayapalan JJ, Mohamed E, Abdul- Rahman PS, Bustam AZ, Khoo ASB, Hashim OH;Application of champedak mannose-binding lectin in the glycoproteomic profiling of serum samples unmasked reduced expression of alpha-2 macroglobulin and complement factor B in patients with nasopharyngeal carcinoma. Electrophoresis 31:14, 2388-2395 Jul 2010
  24. Shingo Kato, Tatsuya Ohno, Kullathorn Thephamongkol, Yaowalak Chansilpa, Yang Yuxing, C.R.Beena Devi, Anita Z. Bustam, Miriam J.C. Calaguas, Rey H. De Los Reyes, Chul-Koo Cho, To Anh Dung, Nana Supriana, Hideyuki Mizuno, Takashi Nakano, Hirohiko Tsujii. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiation Oncology Biol Phys Vol 77 No 3 pg 751-757, 2010
  25. S. Chandramathi, K. Suresh, Z. B. Anita, U. R. Kuppusamy. Attenuation of serum H2O2 and FRAP levels in colorectal cancer patients with intestinal parasitic infection. Mal J Med Sci (2009) 16(2), 15-20
  26. S.Chandramathi,K.Suresh,Z.B.Anita,U.R.Kuppusamy. Elevated levels of urinary hydrogen peroxide, advanced oxidative protein product (AOPP) and malonaldehyde in humans infected with intestinal parasites.Cambridge University Press. Parasitology (2009) 136, 359-363
  27. Emida Mohamed1 ,Puteri Shafinaz Abdul-Rahman1, Saeid Reza Doustjalali1,Yeng Chen1, Boon-Kiong Lim2, Siti Zawiah Omar2, Anita Zarina Bustam3, Vivek Ajit Singh4, Nur Aishah Mohd-Taib5, Cheng-Har Yip5, Onn Haji Hashim1.1Dept of Molecular Medicine, 2Dept. Of Obstetrics and Gynaecology, 3Clinical Oncology Unit, 4Dept. Of Orthopaedic Surgery, 5Dept. Of Surgery, Faculty of Medicine, University of Malaya. Lectin- based electrophoretic analysis of the expression of the 35 kDa inter- - trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. 2008, 29, 2645-2650
  28. S.Chandramathi,K.Suresh,Z.B. Anita,U.R.Kuppusamy. Comparative assessment of urinary oxidative indices in breast and colorectal cancer patients. J cancer Res Clin Oncol (2009) 135:319-325 Published online 29 Aug 2008
  29. Nor ZAINAL, Koh HUI, Ting HANG and Anita BUSTAM. Department of Psychological Medicine and Clinical oncology Unit, Faculty of Medicine, Universiti Malaya. Prevalence of distress in cancer patients undergoing chemotherapy. Asia Pacific Journal of Clinical Oncology 2007; 3: 219-223 (Full paper)
  30. Kei Siong Khoo, Syed Hasan Manzoor Zaidi, Vichien Srimuninnimit, Santai Song, Reena Nair, Corazon A. Ngelangel, Anita Bustam, William H.H Reece, Manfred Lehnert.Gemcitabine and split dose paclitaxel or docetaxel in metastatic breast cancer: a randomized phase II study. European Journal of Cancer 42 (2006) 1797-1806 (Full paper)
  31. Saeid R. Doustjali, Rohana Yusof, Gopala K. Govindasamy, Anita Z. Bustam, Bhanumathy Pillay, and Onn H. Hashim. Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. The Journal of Medical Investigation Vol. 53 No. 1,2, February, 2006 (Full paper)
  32. R.B. Zain, Raja Latifah RJ, Razak IA, Ismail SM, Atiya SA, Hashim BY, Jallaludin A, Bustam AZ, Rahman ZAA, Krishnan G, Kipli NP, Samsudin AR, Nasir WM, Mahadzir WMW, Abraham MT, Norma J, Tay KK, Yuen KM, Cheong SC and Other MOCRI team members. Oral cancer and Precancer in Malaysia The Database and Tissue Resource Bank. Oral Oncology, MacMillan India; 2005. Vol 10: 3-12 (Full paper)
  33. Si Lay Khaing, V Sivaratnam, Siti Zawiah Omar, Anita Zarina Bustam, Mun Kein Seong. Case Report: Small cell carcinoma of uterine cervix in a teen-aged girl a rare occurrence. Malaysian Journal of Obstetrics & Gynaecology 2005: Vol. 8 No. 9: 62-67 (Full paper)
Article in Proceeding
  1. Pawanchek M, Ung N-M*, Bustam A* and Ng K-H. Department of Biomedical Imaging, University of Malaya, *Clinical Oncology Unit, University of Malaya. In-vivo skin dose assessment for breast cancer during radiotherapy treatment using gafchromic film (EBT) detector. Proceedings 29th Annual General Meeting & Scientific Meeting of the College of Radiology Malaysia 3-4 June 2006. (Abstract)
  2. 5.R.B. Zain, R.J. Raja Latifah, I.A. Razak, S.M. Ismail, A.R. Samsuddin, S.A. Atiya, B.Y. Hashim, A. Jallaludin, W.M. Nasir, S.C. Cheong, A.Z.Bustam, W.M.W. Mahadzir, M.T.Abraham, Z.A.A. Rahman, G. Krishnan, N.P. Kipli, J. Norma, K.K. Tay, K.M. Yuen and other MOCRI Team Members. University of Malaya, Universiti Sains Malaysia, Ministry of Health Malaysia, Cancer Research Initiatives Foundation, Malaysia. Oral cancer and precancer research in Malaysia-the database and tissue resource bank. Proceedings of the 10th International Congress on Oral cancer, 19-24th April 2005, Island of Crete, Greece. Oral Oncology Supplement; April 2005; Vol 1 No 1; pp 123 (Abstract)
  3. K.-S. Khoo, M. Zaidi, V. Srimuninnimit, Z. F. Jiang, P. Prem Kumar, A. Bustam, A. H. Villalon, M. Lehnert; National Cancer Centre, Singapore;Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpur, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China.Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC). Vol. 23, 2004 American Society of Clinical Oncology Meeting Proceedings- (Abstract)
  4. Abdul Wahid, A Bustam, F Hayat P Rassiah and U Prasad.Re-treatment of 14 patients with recurrent nasopharyngeal carcinoma using CT simulation and conformal therapy. Radiotherapy and Oncology, Vol. 58 (Supplement1) pg.S97, 6th International Congress of Radiation Oncology Melbourne, Aus, Jan/Feb 2001- (Abstract)

RESEARCH INTEREST

  • Clinical trials any solid tumour in particular breast cancer.

RESEARCH PROJECT

National
  1. 2012 - 2017, Quintiles Janseen Cilaq
    ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer ( Consultant)
  2. 2011 - 2016, High Impact Research (HIR)
    Biobanking of Oral Cancers: An Assessment of Survival, Clinicopathological Parameters, Management Strategies Nutrition and Genetic Susceptibility of Patients ( Consultant)
  3. 2007 - 2015, ScienceFund
    Development of Risk Models and Management Strategies for Oral Cancer ( Consultant)
  4. 2004 - 2015, IRPA
    Oral cancer and precancer in Malaysia-risk factors, prognostic markers, genetic expression and impact on quality of life. ( Consultant)
  5. 2013 - 2015, Roche
    JACOB study:A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating The Efficacy and Safety of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patient with HER-2 Positive Metastatic Gastroesophageal Junction and Cancer ( Principal Investigator(PI))
  6. 2013 - 2015, NONE
    Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors. ( Consultant)
  7. 2013 - 2015, NONE
    Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer ( Consultant)
  8. 2011 - 2013, High Impact Research (HIR)
    Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer ( Consultant)
  9. 2008 - 2012, Wyeth
    An international multi-centre phase III randomised controlled trial of first line treatment of advanced renal cell carcinoma, comparing bevacizumab + interferon-alpha versus bevacizumab + torisel. ( Consultant)
  10. 2008 - 2012, Geran Penyelidikan Universiti Malaya (UMRG)
    Induction and concurrent chemoradiation with cetuximab for treatment of locally advanced Nasopharyngeal Carcinoma ( Consultant)
  11. 2010 - 2011, Postgraduate Research Grant(PPP)
    The Establishment of In-vitro Standard Dose Calibration Curve with High Energy X-ray and Measurement of The Equivalent Dose In Cancer Patients Treated with Radiotherapy Using Biological Dosimetry Technique ( Principal Investigator(PI))
  12. 2007 - 2010, Genentech
    A phase 3 multicentre, randomised, placebo- controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. ( Consultant)
  13. 2008 - 2010, Short Term Research Fund (Vote F)(PJP)
    A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study) ( Consultant)
  14. 2008 - 2010, Geran Penyelidikan Universiti Malaya (UMRG)
    A Prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy (SHARE Study) ( Consultant)
  15. 2007 - 2008, MOH
    A multi-institutional study on the clinical outcome of patients with nasopharyngeal carcinoma (NPC) and the establishment of a Malaysian NPC tissue bank. ( Consultant)
International
  1. 2021 - 2036, Private Funding
    A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PAPILLON) ( Consultant)
  2. 2020 - 2035, Private Funding
    EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess safety and efficacy of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation ( Consultant)
  3. 2010 - 2026, NCC Singapore
    ASCOLT Aspirin in treating patients with Dukes stage C colon or rectal cancer, or high risk Dukes stage B colon cancer that has been completely removed by surgery. ( Consultant)
  4. 2018 - 2023, International Funding
    TROIKA study. Neoadj and adjuvant trastuzumab vs biosimilar in HER 2 positive EBC ( Principal Investigator(PI))
  5. 2010 - 2020, Amgen
    D- CARE A Randomised Double- Blind, Placebo- Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence ( Principal Investigator(PI))
  6. 2016 - 2019, MSD
    MK3475-355 A Randomized, Double-Blind Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Inoperable Locally Recurrent or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355) ( Principal Investigator(PI))
  7. 2015 - 2018, MSD
    A randomised open label phase 3 study of single agent pembrolizumab vs single agent chemo per physician's choice for metastatic triple negative breast cancer-[KEYNOTE-119 study] ( Principal Investigator(PI))
  8. 2010 - 2016, Pfizer
    HKI 3004 Adjuvant breast cancer study in HER2 positive patients using neratinib. ( Principal Investigator(PI))
  9. 2010 - 2016, Pfizer
    Phase 3 open label first line treatment for HER2 positive breast cancer comparing Paclitaxel plus herceptin vs Paclitaxel plus Neratinib. ( Consultant)
  10. 2014 - 2016, Samsung Bioepis
    A Phase III Randomised, Double-Blind,Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting ( Consultant)
  11. 2010 - 2015, Pfizer
    AGILE Axitinib in metastatic renal cell carcinoma patients. ( Consultant)
  12. 2014 - 2015, NUS
    A Prospective Cohort Study of Patients with Malignant Cord Compression ( Consultant)
  13. 2008 - 2014, Genentech
    BEATRICE ( Principal Investigator(PI))
  14. 2008 - 2012, Wyeth
    Phase 3b, randomised, open-label study of Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma. ( Consultant)
  15. 2009 - 2012, Boehringer-Ingelheim
    LUME-Lung 2 An international, multi-centre phase III randomised controlled trial for second line treatment of recurrent, advanced non-small cell lung cancer, comparing pemetrexed + placebo versus pemetrexed + BIBF1120 (a multi-targeted tyrosine kinase inhibitor). ( Principal Investigator(PI))
  16. 2010 - 2012, Amgen
    ASPECCT Panitumumab vs cetuximab for the third line treatment of advanced colorectal cancer. ( Consultant)
  17. 2006 - 2011, Roche
    SATURN/TITAN- A Multicentre, double blind randomized phase 3 study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented or advanced or recurrent or metastatic NSCLC who have not experienced disease progression or unacceptable toxicity during chemotherapy ( Principal Investigator(PI))
  18. 2008 - 2011, Roche
    A Phase 2 Biomarker identification Trial for Erlotinib in patients with Advanced Pancreatic carcinoma (MARK study) ( Principal Investigator(PI))
  19. 2008 - 2011, Pfizer
    A multinational, randomised, open-label, phase 3 study of sunitinib malate vs sorafenib in patients with advanced hepatocellular carcinoma. ( Consultant)
  20. 2009 - 2011, Pfizer
    2009AG-013736 (Axitinib) as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer ( Consultant)
  21. 2003 - 2008, FNCA, Japan
    Concurrent weekly Cisplatin and radiotherapy for advanced cervical cancer. ( Consultant)
  22. 2004 - 2008, GSK
    Phase II, open label study of SB-715992 in subjects with advanced or metastatic breast cancer. ( Consultant)
  23. 2005 - 2008, BMS
    A Phase III trial of novel Epothilone BMS-247550 plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant. ( Principal Investigator(PI))
  24. 2007 - 2008, GSK
    A Phase II, Open-label, Randomised, Multicenter Trial of GW786034 (Pazopanib) in combination with Lapatinib (GW 572016) compared to Lapatinib alone as first line therapy in subjects with advanced or metastatic breast cancer with erb-B2 FISH positive tumours. ( Consultant)
  25. 2001 - 2003, Eli Lilly
    Randomised Phase 2 trial of Gemcitabine combined with a Taxane for metastatic breast cancer. ( Principal Investigator(PI))

CONSULTANCY PROJECT

  • Malaysia Neratinib Expert Meeting, Specialised Therapeutics Asia., Consultant
    06 Nov 2021 - 06 Nov 2021 (National)
  • Breast Cancer Expert Input Forum, MSD, Consultant
    23 Oct 2021 - 23 Oct 2021 (National)
  • Collaborations of Radiation Oncology in Asia, JASTRO
    01 Dec 2016 - 01 Dec 2016 (International)
  • Measurement of Bladder Volume Variations Using Portable Ultrasound Equipment: Introduction of Drinking Protocol, BIIJ
    01 May 2013 - 01 May 2013 (International)
  • Eribulin in Breast Cancer Treatment, Eisai Malaysia Sdn Bhd
    01 Apr 2013 - 01 Apr 2013 (National)
  • The Treatment Outcome of Radical Radiotherapy in Laryngeal Cancer, BIIJ
    01 Feb 2013 - 01 Feb 2013 (International)
  • Penilaian Ubat-Ubatan Kemoterapi, UMMC
    01 Sep 2012 - 01 Sep 2012 (National)
  • Radiation Oncology Training in Malaysia, IAEA
    01 Sep 2012 - 01 Sep 2012 (International)
  • Erlotinib in First Line Egfr Mutation Positive Nsclc, Roche
    01 Aug 2012 - 01 Aug 2012 (National)
  • Head of Panel of Judges for Oral Presentations At Ascomos 2012, Malaysian Oncological Society
    01 Apr 2012 - 01 Apr 2012 (National)
  • Association of Creatinine Clearance With Neutropenia in Breast Cancer Patients Undergoing Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide (Fac), MJM
    01 Feb 2012 - 01 Feb 2012 (National)
  • Asia Pacific Cancer Conference 2011, Malaysian Oncological Society
    01 May 2008 - 01 May 2011 (International)
  • Radioimmunotherapy-Based Treatment of Cancer, BIIJ
    01 Apr 2011 - 01 Apr 2011 (National)
  • Induction Chemotherapy With Paclitaxel, Ifosfamide, and Cisplatin Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced Head and Neck Cancer, BIIJ
    01 Feb 2009 - 01 Feb 2009 (National)
  • International Atomic Energy Agency (Iaea) Project Rca Ras 6040 Improvement in Quality of Radiotherapy for Frequent Cancers in The Region ., International Atomic Energy Agency (IAEA)
    01 Jan 2005 - 01 Jan 2009 (International)
  • Medulloblastoma: Cranial Spinal Junctional Techniques., BIIJ
    01 Jan 2008 - 01 Jan 2008 (National)
  • Poster Presentations Mos 2008, Malaysian Oncological Society
    01 Jan 2008 - 01 Jan 2008 (National)
  • National Cancer Registry, Ministry of Health
    01 Jan 2003 - 01 Jan 2007 (National)
  • Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) Phd(Diagnostic Imaging)(UKM) Phd(Radiotherapy)(UKM), UKM
    01 Jan 2003 - 01 Jan 2003 (National)
  • Annual Scientific Meetings, Malaysian Oncological Society
    01 Jan 2001 - 01 Jan 2003 (National)
  • 37th Malaysia-Singapore Congress of Medicine, Academy of Medicine
    01 Jan 2003 - 01 Jan 2003 (National)
  • Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) Phd(Diagnostic Imaging)(UKM) Phd(Radiotherapy)(UKM), UKM
    01 Jan 2003 - 01 Jan 2003 (National)
  • Mos Annual Scientific Meeting, Malaysian Oncological Society
    01 Jan 2001 - 01 Jan 2001 (National)

PAPER PRESENTED

INVITED SPEAKER
  1. Report of FARO Education and training committee, FARO Council Meeting, FARO (International) (18 Dec 2021 - 18 Dec 2021)
  2. TNBC in Malaysia. Keynote-355 study data & updates , Breast cancer expert input forum, MSD (National) (23 Oct 2021 - 23 Oct 2021)
  3. COVID-19 and Breast Cancer: Setback or Reset?, UMMC Pink October Webinar 2021: COVID-19 and Breast Cancer: Setback or Reset?, Breast cancer resource centre, UMMC (National) (06 Oct 2021 - 06 Oct 2021)
  4. Acute and late toxicities of systemic therapy, MSCT 2020, Clin Oncology Dept, UMMP (National) (11 Sep 2020 - 12 Sep 2020)
  5. Immunotherapy in metastatic breast cancer., Immuno-0ncology symposium in conjunction with World cancer research day, Department of Surgery, FOM, UM (National) (24 Sep 2019 - 24 Sep 2019)
  6. IORT in breast cancer, FARO Annual Meeting 2018, Indonesia radiation oncology society (International) (06 Sep 2018 - 08 Sep 2018)
  7. Antimetabolites, MSCT 2018, Clinical Oncology Dept, UMMC (National) (09 Mar 2018 - 10 Mar 2018)
  8. IORT in breast cancer, Live surgery IORT workshop, Dept of Surgery, UMMC (International) (24 Aug 2017 - 25 Aug 2017)
  9. Antimetabolites, Masterclass in Systemic Cancer Therapy, Dept of Clinical Oncology, UMMC (National) (04 Mar 2017 - 05 Mar 2017)
  10. RADIATION THERAPY IN NEUROBLASTOMA, MASPHO ASM 2016, MASPHO (National) (05 Nov 2016 - 06 Nov 2016)
  11. Epidemiology of cancer and current treatment modalities, 20th Malaysian Conference on Psychological Medicine, Malaysian Psychiatric Association (National) (03 Jun 2016 - 03 Jun 2016)
  12. Development of oncology training in middle income countries: the Malaysian model, AROICON 2015, AROI (International) (29 Nov 2015 - 29 Nov 2015)
  13. Hormonal therapy in breast cancer, 1st UMMC breast cancer public forum, Breast cancer resource centre,UMMC (Others) (18 Oct 2014 - 18 Oct 2014)
  14. An overview of cancer services in Malaysia; a virtual tour of Clin Onco Dept UMMC ; Oncology training in Malaysia, Department of Radiation Oncology, Technical University Munich Seminar, Department of Radiation Oncology, Technical University Munich (International) (04 Apr 2014 - 04 Apr 2014)
  15. Recurrent and metastatic NPC: issues and challenges, NPC research day, NPC Society Malaysia/Universiti Malaya (National) (04 Mar 2013 - 04 Mar 2013)
  16. Radiotherapy planning for breast cancer, Moving from 2D to 3D conformal radiotherapy workshop IAEA MAL 6020, MOH (National) (20 Jun 2012 - 22 Jun 2012)
  17. clinical research forum, 5th national conference on clinical research, ministry of health malaysia (National) (24 Jun 2011 - 24 Jun 2011)
  18. Radiation Therapy for cancer, Seminar perawatan Onkologi, PTj Pembangunan Insan (University) (28 Sep 2010 - 28 Sep 2010)
  19. Pengenalan Kanser Wanita dan Rawatan, Seminar kanser wanita dari perspektif biopsikososial, PTj Kebajikan Perubatan, PPUM (National) (11 Nov 2008)
  20. Oncology Endpoints: Their relevance in advanced cancer. , Palliative Care Symposium: Clinical Decision making and Ethics in Advanced Cancer, Faculty of Medicine, UM (National) (18 Apr 2007)
  21. An overview of radiation therapy in cancer treatment., A Continuous Professional Development Course in Radiotherapy, Radiology Dept., FOM, UM (National) (20 Dec 2005 - 22 Dec 2005)
  22. Radiotherapy of BAVM, Basic Neuro-interventional Course, Radiology Dept, FOM, UM (University) (11 Mar 2004 - 12 Mar 2004)
  23. Follow-up of treated breast cancer patients, MOS Annual Scientific Meeting, MOS (National) (20 Sep 2002 - 22 Sep 2002)
  24. Hormone therapy, Oncology in Palliative Care Seminar, Hospis Malaysia (National) (29 Jul 2001)
EVENT ORGANISER
  1. Not applicable, APCC 2011, MOS (International) (10 Nov 2011 - 11 Nov 2011)
  2. None, MOS Annual Scientific Meeting, MOS (National) (28 Sep 2002 - 30 Sep 2001)
ORAL PRESENTER
  1. Country Report and Report of 3rd RTC, Final review meeting IAEA RAS6086 project, IAEA (International) (13 Dec 2021 - 15 Dec 2021)
POSTER PRESENTER
  1. Outcome of malignant CNS tumours in young children from a single institution in Malaysia: 15-year experience with HEAD START 1 and 2 protocols, SIOP 2018, SIOP (International) (16 Nov 2018 - 18 Nov 2018)
  2. Prospective controlled study on the role of scalp hypothermia to prevent chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy., APCC 2011, MOS (International) (10 Nov 2011 - 11 Nov 2011)
  3. Psycho-Oncology Referrals- A Single-Centre Review from Malaysia, IPOS 12th World Congress of Psycho-Oncology (International) (25 May 2010 - 29 May 2010)
  4. DEVELOPMENT OF SPECIALIST TRAINING PROGRAMME IN CLINICAL ONCOLOGY: THE MALAYSIA EXPERIENCE, ICARO 2009, IAEA (International) (27 Apr 2009 - 29 Apr 2009)
PRESENTER
  1. Country report, Progress Review Meeting of RAS6086, IAEA (International) (25 Nov 2020 - 26 Nov 2020)
  2. Covid 19 situation in Malaysia; impact on radiotherapy services, 1st FARO webinar, ISRO (International) (25 Sep 2020 - 25 Sep 2020)
  3. Clinical Oncology training in Malaysia, 1st FARO Council Member meeting, Japan as host country (International) (30 May 2015 - 30 May 2015)
  4. Key Performance Indices , Ministry of Health Workshop on Quality Assurance in Radiotherapy , MOH (National) (01 Aug 2006)
  5. Concurrent chemoradiotherapy for cervical cancer (CERVIX-III), FNCA workshop on Radiation Oncology, FNCA (International) (13 Dec 2004 - 17 Dec 2004)
OTHERS
  1. not applicable, ESMO Penang, MOS and ESMO (International) (22 Jan 2015 - 25 Jan 2015)
  2. Lung cancer, World conference on lung cancer, IASLC (International) (27 Oct 2013 - 30 Oct 2013)
  3. Breast cancer, Asia Pacific Breast Cancer Summit (International) (12 Apr 2013 - 13 Apr 2013)
  4. Jacob study for stomach cancer, JACOB study Investigator Meeting, Roche (International) (06 Mar 2013 - 08 Mar 2013)
  5. Oral presentations, ASCOMOS 2012, MOS (National) (08 Sep 2012 - 08 Sep 2012)
  6. Report on Lung cancer statistics, NCR Report Writing Workshop for year 2003-2005, MOH (National) (02 Mar 2007 - 04 Mar 2007)
  7. None, 37th Malaysia-Singapore Congress of Medicine, Academy of Medicine (National) (05 Sep 2003 - 07 Sep 2003)

ACADEMIC/PROFESSIONAL SERVICES

Evaluation
  1. (2021) Master of Clinical Oncology Fina Examination, University, (Internal Examiner)
  2. (2021) Master of Clinical Oncology Part 2 Examination, University, (Internal Examiner)
  3. (2021) part 1, 2 and Final Examinations Master of Clinical Oncology May 2021, (Internal Examiner)
  4. (2021) Tretament outcome for local recurrent nasopharyngeal carcinoma in UMMCfrom 2010-2017, (Internal Examiner)
  5. (2021) Development of real-time radioluminescent dosimetry system for medical application , (Panelist)
  6. (2021) Master of Clinical Oncology Part 1 Exam May 2021, University, (Internal Examiner)
  7. (2021) Master of Clinical Oncology Part2 Exam May 2021, University, (Internal Examiner)
  8. (2021) The Association of Physical Activity and Quality of Life Among Malaysian Breast Cancer Survivors, University, (Internal Evaluator)
  9. (2021) Treatment Outcome for Local Recurrent Nasopharyngeal Carcinoma in Ummc from 2010-2017, University, (Internal Examiner)
  10. (2021) Judge for Proffered/Research Paper At Faro 2021 Scientific Meeting, International, (External Evaluator)
  11. (2021) Judge for Profferred (Research) Papers At 5th Faro Scientific Meeting, International, (External Evaluator)
  12. (2021) Household Catastrophic Health Expenditure from Oral Potentially Malignant Disorders and Oral Cancer in Public Healthcare of Malaysia, International, (Reviewer)
  13. (2021) Household Catastrophic Health Expenditure from Oral Potentially Malignant Disorders and Oral Cancer in Public Healthcare of Malaysia, International, (Reviewer)
  14. (2021) Master of Clinical Oncology Part 1 Examination, University, (Internal Examiner)
  15. (2020) Mutation profile of breast cancer in Malaysian patients, (Reviewer)
  16. (2020) Role of vitamin D in preventing colororectal carcinogenesis: Systemayic review, (Reviewer)
  17. (2020) IMPACT OF PHYSICAL ACTIVITY ON PROGNOSIS AND QUALITY OF LIFE OF BREAST CANCER PATIENTS IN MyBCC STUDY , (evaluator)
  18. (2020) Examiner for part 1, part 2 and Final exam for Master of clinical Oncology, (Internal Examiner)
  19. (2020) MAGNITUDE AND FACTORS ASSOCIATED WITH THROMBOSIS AMONG CANCER PATIENTS RECEIVING CHEMOTHERAPY AT OCEAN ROAD CANCER INSTITUTE. , (Reviewer)
  20. (2020) Evaluate proposal defense by MSc candidate- Lee Yi Lin (17219644), (evaluator)
  21. (2020) Examiner for OSCE, (Internal Examiner)
  22. (2019) Logbook and continuous assessment, (Internal Examiner)
  23. (2019) Marking Part 2 COQ exam scripts. Examiner for Final Examination , (Internal Examiner)
  24. (2019) Jawatankuasa Pemeriksa bagi Peperiksaan ljazah Sarjana Sains Perubatan secara Penyelidikan /Kursus dan Penyelidikan (bagi komponen penyelidikan) i)Berkaitan dengan peperiksaan disertasi, menimbang laporan pemeriksa di atas disertasi seorang calon dan mengambil sesuatu keputusan termasuk mengenai tahap pencapaian disertasi itu ; ii) Dalam keadaan tertentu Jawatankuasa Pemeriksa boleh menjalankan peperiksaan viva dan / atau ujian lain difikirkan sesuai ; dan iii) Melaporkan kepada Senat mengenai apa-apa perkara yang berkaitan dengan mutu dan/atau perjalanan sesuatu peperiksaan., (Exam committee)
  25. (2019) All Trans Retinoic Acid (ATRA) Inhibits Telomerase Expression of BeWo Choriocarcinoma Cell (ATCC CCL-98) , (Reviewer)
  26. (2019) Exam script marker, (Internal Examiner)
  27. (2019) Treatment outcome of brain metastases in UMMC. , (Internal Examiner)
  28. (2018) Intracranial angiomatoid Fibrous histiocytoma with Hodgkin lymphoma , (Reviewer)
  29. (2018) The Great Masquerade: Empyema Thoracis as an Unusual Presentation of Primary Lung Malignancy , (Reviewer)
  30. (2017) Peperiksaan OSCE Stage 2 MBBS - RSA 1, (Internal Examiner)
  31. (2017) Relapsed Lymphoma Mimicking Venous Ulcer : A Case report for MJM, (Reviewer)
  32. (2017) Evaluation of research proposal under FRGS grant application, (Panel Penilai)
  33. (2017) Marking of exam scripts for Master of Clinical Oncology Part 1 May 2017 Exam, (Internal Examiner)
  34. (2017) Examiner for MD degree. Title of thesis: Management of psychological distress in cancer patients. MHB130001, (Internal Examiner)
  35. (2017) Lapatinib, trastuzumab and Capecitabine prolonged the survival of HER2-positive gastric cancer with leptomeningeal carcinomatosis: a case report., (Reviewer)
  36. (2017) "Stress levels during the journey of cancer treatment" , (Reviewer)
  37. (2017) Ref.: Ms. No. MJM-D-17-00148 Breast Ductal Carcinoma to Metaplastic Carcinoma- A Change in Cancer Morphology - A Case Report and Literature Review The Medical Journal of Malaysia , (Reviewer)
  38. (2017) Marking MCO Part 1 exam scripts , (Internal Examiner)
  39. (2017) Outcome of patients with cord compression treated in UMMC. Master of Clinical Oncology Final Exam, (Internal Examiner)
  40. (2017) Review and select abstracts for FARO 2017 scientific meeting, (Reviewer)
  41. (2017) Comparison of the seventh and eight editions of the UICC/AJCC staging system for NPC; analysis of 1317 patients treated with IMRT at two centres , (Reviewer)
  42. (2017) Chemotherapy for metastatic colon cancer -No effect on survival when the dose is reduced due to side-effects. BMC cancer , (Reviewer)
  43. (2016) Evaluate suitability of research proposal/project for consideration of sciencefund (MOSTI) research grant, (Evaluating panel)
  44. (2016) Treatment Of heavily pre-treated metastatic breast cancer with Eribulin: First local experience in Sabah. , (Reviewer)
  45. (2016) Master of Clinical Oncology Part 1, 2 and Final Exams , (Internal Examiner)
  46. (2016) Triple negative breast cancer survival and prognostic factors., (Internal Examiner)
  47. (2016) Evaluate the suitability of the following article for publication in BMC Cancer journal: Chemotherapy on metastatic colon cancer:No effect on survival when dose is reduced due to side-effects., (Reviewer)
  48. (2016) Chemotherapy Induced Neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort Study, (Reviewer)
  49. (2016) Management of psychological distress in cancer patients: Focus on brief mindful therapy, (Assessor)
  50. (2016) Medical Journal Malaysia: Gastric ulcer than turned out to be metastasis of a synovial sarcoma: A case report and literature review., (Reviewer)
  51. (2016) Pretreatment Expression of Blood and Tissue Biomarkers as a Predictor of Tumor Response After Neoadjuvant Chemoradiation in Rectal Cancer, (Reviewer)
  52. (2016) Review research abstracts submitted for FARO 2016. Provide scoring for each as per guideline from organising commitee., (Assessor)
  53. (2015) Symptoms burden and QoL. Comparison between CAM and non-CAM users during breast cancer chemotherapy in 2 public hospitals in Malaysia., (Internal Examiner)
  54. (2015) Palliative to curative treatment: A case of stage 4 mucinous adenocarcinoma successfully treated with metronomic capecitabine in combination with bevacizumab and surgery., (Reviewer)
  55. (2015) marking exam scripts and viva voce , (Internal Examiner)
  56. (2014) Editorial board member for International Journal of Recent Research in Life Sciences (IJRRLS), (Editor)
  57. (2013) JUMMEC Case study: Squinting eyes: A presenting complaint in a young adult with glioblastome multiforme. , (Reviewer)
  58. (2013) MEASUREMENT OF BLADDER VOLUME VARIATIONS USING PORTABLE ULTRASOUND EQUIPMENT: INTRODUCTION OF DRINKING PROTOCOL , (Reviewer)
  59. (2013) Master of Clinical Oncology Part 1,2 and Final Exam , (Internal Examiner)
  60. (2013) Appointed as external assessor from UCSI University to assess suitability of an academic staff from UCSI for promotion from assoc. prof. to full prof. , (External Assessor)
  61. (2013) Metastatic melanoma to the stomach; a case report , (Reviewer)
  62. (2013) The treatment outcome of radical radiotherapy in laryngeal cancer. , (Reviewer)
  63. (2013) Survival of primary lung cancer patients treated in Brunei darussalam , (External Examiner)
  64. (2013) MJM Chemotherapy extravasation at Hospital Pulau Pinang Malaysia , (Reviewer)
  65. (2012) Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC), (Reviewer)
  66. (2009) Induction chemotherapy with paclitaxel, ifosfamide and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer., (Reviewer)
  67. (2008) Medulloblastoma: Cranial spinal junctional techniques., (Reviewer)
  68. (2008) Poster presentations
  69. (2008) Advanced Diploma in Nursing Oncology (UM)
  70. (2008) Bachelor in Medical Sciences (Diagnostic Imaging)(UKM) Bachelor in Medical Sciences (Radiotherapy)(UKM) PhD(Diagnostic Imaging)(UKM) PhD(Radiotherapy)(UKM)
  71. (2006) Master of Clinical Oncology Part 1 Exam, (Internal Examiner)
Contribution to external organisation
  1. (2022) Chair of Faro Education and Training Committee, International, (Resource Person)
  2. (2021) Neratinib Expert Meeting, National, (Expert Advisor)
  3. (2021) Malaysia Neratinib Expert Meeting, National, (Expert Advisor)
  4. (2021) Msd Expert Input Forum On Pembrolizumab in Tnbc (Studies Keynote 355 and 522), National, (Expert Advisor)
  5. (2021) Msd Breast Cancer Advisory Board Meeting, National, (Expert Advisor)
  6. (2021) National Project Coordinator for Iaea Project Ras6086, International, (Technical Advisor)
  7. (2019) National Project Coordinator forRCA/IAEA RAS6086 project, IAEA
  8. (2018) RCA-IAEA project RAS6086 - Strengthening cancer management programmes in RCA states parties through collaboration with national and regional radiation oncology societies., IAEA
  9. (2018) Evaluate the suitability of eribulin in patients who have failed one line of chemo in the advanced metastatic setting., Drug Control Authority, MOH Malaysia
  10. (2017) Evaluate the suitability of TS-1 tablet in terms of bioequivalence as compared to TS-1 capsule to be used for the same clinical indications., DCA, MOH
  11. (2016) Evaluate suitability of research project/proposal for consideration of sciencefund(MOSTO) research grant, Universiti Malaya
  12. (2016) Evaluate the suitability of tegafur in the treatment of NSCLC for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia
  13. (2016) Evaluate the suitability of tegafur in the treatment of pancreatic cancer for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia
  14. (2016) Evaluate the suitability of afinitor in the treatment of advanced renal cell carcinoma in patients with disease progression following treatment with anti VEGF, Drug Control Authority, Ministry of Health, Malaysia
  15. (2016) Evaluate the suitability of tegafur in the treatment of colorectal cancer for the purpose of additional indication approval., Drug Control Authority Ministry of Health Malaysia
  16. (2016) Evaluate the suitability of cyramza in the treatment of stomach/GOJ tumours, colorectal and NSCLC for the purpose of registration., National Pharmaceutical Control Bureau, MOH Malaysia
  17. (2015) Evaluate suitability of nindetanib esilate in advanced NSCLC for the purpose of new drug registration., Pihak Berkuasa Kawalan Dadah Biro Pengawalan Farmaseutikal Kebangsaan Kementerian Kesihatan Malaysia
  18. (2015) Evaluate suitability of vismodegib in advanced basal cell carcinoma for the purpose of new drug registration., Pihak Berkuasa Kawalan Dadah Biro Pengawalan Farmaseutikal Kebangsaan Kementerian Kesihatan Malaysia
  19. (2013) Root cause analysis, UMMC
  20. (2012) Penilaian ubat-ubatan kimoterapi, Pusat perubatab Universiti Malaya
  21. (2012) Radiation oncology curriculum in developing countries, IAEA
  22. (2009) Clinical Oncology Specialty Committee, Universiti Malaya
  23. (2008) Organising Committee for APCC 2011, Malaysian Oncological Society
  24. (2005) International Atomic Energy Agency (IAEA) Project Coordinator for project RCA RAS 6040 Improvement in Quality of Radiotherapy for Frequent Cancers in the Region., IAEA
  25. (2005) To give input with regards to the conduct and management of clinical trials and in particular industry sponsored trials managed by Clinical Investigation Centre, UM, Clinical Investigation Centre, Faculty of Medicine , UM
  26. (2003) Structuring, data collection, analysis and report writing, National Cancer Registry
  27. (2001) Medical Advisory Committee member. Advise on clinical issues at UMMC., UMMC
Contribution to event
  1. (2021) Report of Faro Etc 2021 Activities, International, (Participant)
  2. (2021) Report of Faro Etc Activities 2021, International, (Participant)
  3. (2021) Nccom E-Portfolio, National, (Panelist/Moderator)
  4. (2021) Chairperson of Scientific Session, International, (Panelist/Moderator)
  5. (2021) Scientific Committee, National, (Event Organiser)
  6. (2021) Scientific Committee, National, (Event Organiser)

SUPERVISION

Under Graduate Students
  1. (2012) Describing the clinical management and resource use of solid tumour patients with chemotherapy-related febrile neutropenia in UMMC
Postgraduate Student
Master
  1. (2020) PROSPECTIVE EVALUATION OF RADIATION-INDUCED LATE TOXICITIES IN HEAD AND NECK CANCERS IN UNIVERSITY MALAYA MEDICAL CENTRE, Nurhidayu Salimin
  2. (2020) -, JASMIN MUNCHAR BINTI ELIAS
  3. (2020) -, SITI MARIAM BINTI YACOB
  4. (2020) -, SHAZWANI SHABUDIN
  5. (2020) -, AMIR ARIF AHMANUL
  6. (2020) -, NUR NADYA BINTI MOHAMAD NASIP
  7. (2020) -, CHIA WEI JONATHAN CHEW
  8. (2020) -, MOHD FAIRUZ JAYAH
  9. (2020) -, MUN CHEE CHONG
  10. (2020) -, ADELINE MICHELLE MATHEW
  11. (2020) -, JIAN WEN LEE
  12. (2020) -, WEI QUAN WONG
  13. (2020) -, FION TEO
  14. (2020) -, ILEENA ABDUL MUIN
  15. (2020) -, OOI PO LIN
  16. (2020) -, NUR HIDAYAH HABIL
  17. (2020) Comparison of dosimetric coverage of RTOG and ESTRO-defined target volumes for chest wall and supraclavicular fossa radiotherapy with standard field-based radiotherapy in University Malaya Medical Centre., Chiam Poh Jeann
  18. (2020) clinical supervision, Tan Li Mei
  19. (2020) clinical supervision, Tang Shir Ley
  20. (2020) clinical supervision, Nor Faizah Abd Muin
  21. (2020) clinical supervision, Liew Zhi Hao
  22. (2020) clinical supervision, Jasmin Munchar
  23. (2020) clinical supervision, Fatimahtulzahrah saparmin
  24. (2020) clinical supervision, Daniel Gan
  25. (2020) clinical supervision, Chen May Feng
  26. (2020) clinical supervision, Anbarasan Anbazagan
  27. (2019) clinical supervision, Shazlin Hasbullah
  28. (2019) Clinical supervision, Tun Mohd Azlan Mohd Nor
  29. (2019) Clinical supervision, Sum Ying Ying
  30. (2019) Clinical supervision, Shazlin Md Hasbullah
  31. (2019) clinical supervision, Rufus Jesudas
  32. (2019) clinical supervision, Nadiah Zainal
  33. (2019) clinical supervision, Nurul Iman Fathi
  34. (2019) Clinical supervision, Mohd Fahim Abd Rahman
  35. (2019) clinical supervision, Magdalene Anuth Ranjit
  36. (2019) clinical supervision, Nor Hayati Hashim
  37. (2019) Clinical supervision, Jason Lai Shen Chang
  38. (2019) clinical supervision, Chan Ming Jun
  39. (2019) Cancer Trend, Utilisation of Resources and Workload Analysis at a Tertiary Academic Hospital in a Developing Country, Daniel Gan Eng Hwee
  40. (2018) Clinical supervision, Tang Seng Paul
  41. (2018) -, CHIAM POH JEANN
  42. (2018) -, ANNANDAKUMAR BALAKRISHNAN
  43. (2018) -, AHMAD NAUFAL BIN MD ALWI
  44. (2018) -, CHEN MAY FENG
  45. (2018) -, DANIEL GAN ENG HWEE
  46. (2018) Clinical supervision, Noor Nabila Mohamed
  47. (2018) -, NOOR NABILA BINTI MOHAMAD
  48. (2018) -, VICKEE RAJESWARAN
  49. (2018) Clinical supervision, Nisha Mohd Shariff
  50. (2018) -, IZZATI BINTI WAN MAHARUDDIN
  51. (2018) Clinical supervision, Chiam Poh Jeann
  52. (2018) -, SUM YING YING
  53. (2018) -, MOHD FAHIM BIN ABD RAHMAN
  54. (2018) Clinical supervision, Ahmad Naufal Md Alwi
  55. (2018) -, CHONG CHAN TENG
  56. (2018) -, IZZATI BINTI ROSLI
  57. (2017) -, RIZMA BINTI MOHD ZAID
  58. (2017) -, ENG JIE YI
  59. (2017) -, GOH HUEY LUEN
  60. (2017) -, AUDI ADAWIAH BINTI SULAIMAN SHAH
  61. (2017) -, YUSRA HADI
  62. (2017) -, NUR FA'IZAH BINTI AB MUIN
  63. (2017) -, ARDIF BIN DAMIRI
  64. (2017) -, KHAMINI A/P THARUMARAJAH
  65. (2017) -, MOHD ASYRAF BIN MD NOR @ MOHD ZAIN
  66. (2017) -, ALDRIN JASPER PLACIDUS
  67. (2017) -, NORHIDAYU BT SALIMIN
  68. (2017) -, TANG SHIR LEY
  69. (2017) -, TANG SEEN PAUL
  70. (2017) -, NURUL IMAN BINTI FATHI
  71. (2017) -, SANDYA SUBRAMANIAM
  72. (2017) -, RANGASAMY A/L RAMACHANDRAN
  73. (2017) -, PUWANESWARRY A/P MIUNDY
  74. (2017) -, TUN MOHD AZLAN BIN MOHAMED NOR
  75. (2017) Chemoport usage and complication rates in UMMC., Heng Fook Yew
  76. (2017) Acute radiation related oral toxicities in HNSCC patients in UMMC: A prospective study, Kumutha
  77. (2017) Timing And Outcome Of Palliative Chemotherapy, Teh Hooi Lay
  78. (2017) clinical supervision, Patricia Shamani
  79. (2017) Palliative radiotherapy for advanced cancer: Are we giving it to the right patient at the right time?, Syadwa
  80. (2017) clinical supervision, Puvaneswarry
  81. (2017) clinical supervision, Teh Hooi Lay
  82. (2017) clinical supervision, Aldrin Jasper
  83. (2017) clinical supervision, Tan Li Mei
  84. (2017) clinical supervision, Mohd Asyraf
  85. (2017) clinical supervision, Kumutha
  86. (2017) clinical supervision, Eng Jie Yi
  87. (2017) clinical supervision, Syadwa
  88. (2017) clinical supervision, Rosdiana
  89. (2016) clinical supervision, Lee Hong Moi
  90. (2016) clinical supervision, Lee Dai Wee
  91. (2016) clinical supervision, Sangeeta
  92. (2016) -, SANGEETA VAHNALINGAM
  93. (2016) clinical supervision, lavannia
  94. (2016) -, NAJIHAH BINTI ABU BAKAR
  95. (2016) clinical supervision, hadi
  96. (2016) -, NGU MING RUEY
  97. (2016) clinical supervision, Fiona
  98. (2016) -, NIK ROZLIN ELINI BINTI MOHD SHUHAIMI
  99. (2016) clinical supervision, chan ming jun
  100. (2016) -, SYAFIRIN BIN AB SANI
  101. (2016) -, LEE DAI WEE
  102. (2016) -, NARENDRAN A.L KORISATAN
  103. (2016) -, SOMA BAVANI SIVARAJ
  104. (2016) clinical supervision, syafirin
  105. (2016) -, CHAN MING JUN
  106. (2016) -, VANCE KOI YUNG CHEAN
  107. (2016) clinical supervision, Vance Koi
  108. (2016) -, ANGEL KWAN KHOR NEE
  109. (2016) -, TEH HOOI LAY
  110. (2016) -, NUR JIHAN BT IRWAN TAN
  111. (2016) clinical supervision, Tan Li Mei
  112. (2016) -, EZNAL IZWADI MOHD MAHIDIN
  113. (2016) -, LEE HONG MOI
  114. (2016) -, PATRICIA SHAMANI A/P SOOSAINATHAN
  115. (2016) -, LAVANNIA A/P RAJARATENAM
  116. (2016) -, SRI KISHA A/P SUBRAMANIAM
  117. (2015) clinical supervision, Hadi Jalil
  118. (2015) clinical supervision, Kumutha a/p Chalaya
  119. (2015) -, FELIX LIAU YEE FAN
  120. (2015) clinical supervision, Nik Rozlin Elini Mohd Shuhaimi
  121. (2015) -, KUMUTHA A/P CHALAYA
  122. (2015) clinical supervision, Heng Fook Yew
  123. (2015) clinical supervision, Lee Hong Moi
  124. (2015) clinical supervision, Ngu Ming Ruey
  125. (2015) clinical supervision, Alagu Manthiram Ramasamy
  126. (2015) -, NISHA BINTI MOHD SHARIFF
  127. (2015) -, ROSDIANA BINTI ABD RAHIM
  128. (2015) clinical supervision, Felix Liau Yee Fan
  129. (2015) Chemoport usage and its complications in the oncology dept, UMMC, Heng Fook Yew
  130. (2015) -, SYAZNI BINTI BADROL HISHAM
  131. (2015) clinical supervision, Nur Jihan Irwan Tan
  132. (2015) clinical supervision, Ravivarma Prathapan
  133. (2015) clinical supervision, Rosdiana Abd Rahim
  134. (2015) clinical supervision, Syazni Badrol Hisham
  135. (2015) -, RAVIVARMA PRATHAPAN
  136. (2015) -, HADI BIN AB. JALIL
  137. (2015) -, HENG FOOK YEW
  138. (2015) -, ALAGU MANTHIRAM A/L RAMASAMY
  139. (2015) clinical supervision, Nisha Mohd Shariff
  140. (2014) Clinical supervision, Gan Ben Jin
  141. (2014) -, LIM YI WAY
  142. (2014) -, GAN BENG JIN @ BENJAMIN GAN
  143. (2014) Clinical supervision, Narendran K
  144. (2014) Timing and outcome of palliative radiotherapy., Syadwa
  145. (2014) Clinical supervision, Lim Yaeh Ni
  146. (2014) -, SYADWA BINTI ABDUL SHUKOR
  147. (2014) Clinical supervision, Shadwa
  148. (2014) -, LIM YUEH NI
  149. (2014) Clinical supervision, Lim Yi Way
  150. (2013) -, CHOONG SWEE HSIA
  151. (2013) -, FIONA SULING LIAN
  152. (2013) -, NOOR ZAFIFAH BINTI ZAKARIA
  153. (2013) -, KHAIRIYAH BINTI SIDEK
  154. (2013) -, TEO YIN KEONG
  155. (2013) -, SOW WEN JEN
  156. (2013) Clinical supervision, Tan Li Mei
  157. (2013) -, TAN LI MEI
  158. (2013) Clinical supervision, Choong Swee Hsia
  159. (2013) Clinical supervision, Khairiyah Sidek
  160. (2013) Clinical supervision, Noor Zafifah Zakaria
  161. (2013) Clinical supervision, Sow We Jen
  162. (2013) Clinical supervision, Fiona Suling Lian
  163. (2013) Clinical supervision, Teo Yin Keong
  164. (2012) Clinical supervision, Sucharit Pongprakyun
  165. (2012) Clinical supervision, Prathepamalar Yehgambaram
  166. (2012) Clinical supervision, Eznal Izwadi Mohd Mahidin
  167. (2012) Clinical supervision, Ang Tick Suan
  168. (2012) adjuvant trastuzumab in early breast cancer: a`retrospective cohort study in two oncology centres in malaysia, Harissa Husainy Hasbullah
  169. (2011) -, INA SHALINY A/P DURAISAMY
  170. (2011) Clinical supervision, Han Albert Dicken
  171. (2011) Clinical supervision, Junie Khoo Yu Yen
  172. (2011) Clinical supervision, Ng Boon Huat
  173. (2011) Clinical supervision, Marfuah Nik Eezamuddeen
  174. (2011) -, MARFU'AH BINTI NIK EEZAMUDDEEN
  175. (2011) Clinical supervision, Ina Shaliny Duraisamy
  176. (2011) Clinical Supervision, Santhi Nadarajan
  177. (2011) Clinical supervision, Nahjatul Kursyiah Abd Ghafar
  178. (2011) Clinical supervision, Soma Bavani Sivaraj
  179. (2011) Clinical supervision, Tang Weng Heng
  180. (2011) Clinical supervision, Winnie Ng Nyek Ping
  181. (2011) -, HAN ALBERT DICKEN
  182. (2011) -, JUNIE KHOO YU-YEN
  183. (2010) -, ASTRID SINARTI BINTI HASSAN
  184. (2010) Clinical supervision, Arnil George Sirimanne
  185. (2010) Clinical supervision, Astrid Sinarti Hassan
  186. (2010) Clinical supervision, Leong Siew Mooi
  187. (2010) Clinical supervision, Malwinder Singh Sandhu
  188. (2010) Clinical supervision, Sunitha Kumaran
  189. (2010) -, SUNITHA A/P KUMARAN
  190. (2010) Clinical supervision, Tan Chih Kiang
  191. (2010) Radiation-induced hypothyroidism following radical radiotherapy for head and neck cancer, Lim Chun Sen
  192. (2010) The Establishment of In-vitro Standard Dose Calibration Curve with High Energy X-ray and Measurement of The Equivalent Dose In Cancer Patients Treated with Radiotherapy Using Biological Dosimetry Technique, Halim Abdul Rahman
  193. (2010) -, MALWINDER SINGH SANDHU
  194. (2010) PROTEOMICS STUDIES OF SERA OF PATIENTS WITH NASOPHARYNGEAL CARCINOMA: A LECTIN-BASED APPROACH, RAMARAO A/L SERIRAMALU
  195. (2010) Clinical supervision, Wong Yoke Fui
  196. (2009) Clinical supervision, Noor Syuhadah A. Karim
  197. (2009) Symptoms prevalence, characteristics and coping strategies among adult oncology patients., Nor Aziyan Yahya
  198. (2009) Clinical supervision, Atiliana Mohamed Adib
  199. (2009) Clinical supervision, Harissa Husainy Hasbullah
  200. (2009) Clinical supervision, Muthukumaran
  201. (2009) Clinical supervision, Vaishnavi Jeyasingam
  202. (2008) Clinical supervision, Suhana Yusak
  203. (2008) Clinical supervision, Siti Zaleha Md Sani
  204. (2008) Concurrent chemoradiotherapy in H&N cancer, Mastura Md Yusuf
  205. (2008) Clinical supervision, Fong Chin Heng
  206. (2008) Clinical supervision, Cheah Soon Keat
  207. (2008) Clinical supervision, Noorzulali Haron
  208. (2008) Clinical supervision, Natasha Mohd Hashim
  209. (2007) Proteomic studies in patients with NPC: lectin-based approach, Ramarao a/l Seriramalu
  210. (2007) Clinical supervision, Lee Wei Ching
  211. (2007) Clinical supervision, Ibtisam Muhammad Nur
  212. (2007) Clinical supervision, Hafizah Zaharah Ahmad
  213. (2007) Clinical supervision, Flora Chong Li Tze
  214. (2007) Analysis of breast cancer in elderly women:cohort of 1994-2004 treated in UMMC, Vincent Phua Chee Ee (University of Malaya (UM))
  215. (2006) Concurrent chemoradiation for patients with nasopharyngeal carcinoma treated in UMMC between 2001 and 2003., Nik Muhd Aslan Abdullah (University of Malaya (UM))
  216. (2006) Clinical supervision, Yu Kong Leong
  217. (2006) Clinical supervision, Ros Suzanna Ahmad Bustamam
  218. (2006) Clinical supervision, Lau Kah Liew
  219. (2006) Clinical supervision, Hayani Abdul Wahid
  220. (2005) Cinical supervision, Kua Voon Fong
  221. (2005) Clinical supervision, Chandra Kumar A/l Krishnan
  222. (2005) Clinical supervision, Chan Wee Han
  223. (2005) Clinical supevision, Ng Poh Huat
  224. (2005) In vivo skin dose assessment for breast cancer dring radiotherapy treatment using gafchromic film (EBT) detector, Mahzom Pawanchek (University of Malaya (UM))
  225. (2004) The evolution of 2-D to 3-D radiation therapy practice in the treatment of nasopharyngeal carcinoma., Sin Sze Yarn (A0800108)
  226. (2004) Clinical supervision, Yang Rashidi Abdullah
  227. (2004) Clinical supervision, Wan Zamaniah Wan Ishak
  228. (2004) Clinical supervision, Rozita Abdul Malik
  229. (2004) Clinical supervision, Fabian Lee Wei Yuen
  230. (2003) Clinical supervision, Tan Boon Seang
  231. (2003) Clinical supervision, Adlan Suhaimi Ahmad
  232. (2003) Assessment of patients with carcinoma of the cervix treated with definitive radiotherapy at UMMC., Si Lay Khaing (University of Malaya (UM))
  233. (2002) Clinical supervision, Farah Zaffar Hayat
  234. (2002) Clinical supervision, Azura Deniel

TEACHING

Master
  1. (2021) Master of Clinical Oncology Part 2 Clinical Teaching
  2. (2020) MAGT6300 - Magt6300
  3. (2020) MAGT -
  4. (2019) MAGT -
  5. (2019) MAGT6300 - Magt6300
  6. (2018) MAGT -
  7. (2018) MAGT - Master of Clinical Oncology
  8. (2016) MAGT - Master of Clinical Oncology
  9. (2015) MAGT - Master of Clinical Oncology
  10. (2015) Master of Clinical Oncology
  11. (2014) MAGT - Master of Clinical Oncology
  12. (2013) MAGT - Master of Clinical Oncology
  13. (2012) MAGT - Master of Clinical Oncology
  14. (2011) MAGT - Master of Clinical Oncology
  15. (2011) Master of Medical Physics
  16. (2010) MAGT - Master of Clinical Oncology
  17. (2009) MAGT - Master of Clinical Oncology
  18. (2008) MAGT - Master of Clinical Oncology
  19. (2007) MAGT - Master of Clinical Oncology
  20. (2006) MAGT - Master of Clinical Oncology
  21. (2006) Master of Medical Physics
  22. (2005) MAGT - Master of Clinical Oncology
  23. (2005) Master of Otorhinolaryngology
  24. (2005) Master of Medical Physics
  25. (2004) Master of Obstetrics & Gynaecology
  26. (2004) Master of Medical Physics
  27. (2004) Master of Internal Medicine
  28. (2004) MAGT - Master of Clinical Oncology
  29. (2003) NA - Master of Medical Physics
  30. (2003) Master of Clinical Oncology
  31. (2002) Master of Medical Physics
  32. (2002) Master of Clinical Oncology
  33. (2001) Master of Medical Physics
  34. (2000) Master of Medical Physics
Bachelor/First Degree
  1. (2021) UMMP - Universiti Malaya Medical Programme
  2. (2021) UMMP -
  3. (2021) UMMP -
  4. (2020) MID2005 - Basic Medical Science Iii
  5. (2020) UMMP -
  6. (2018) UMMP - Ummp
  7. (2018) UMMP -
  8. (2015) ONCOLOGY - Ummp
  9. (2015) Ummp
  10. (2007) Mbbs
  11. (2007) Basic Degree in Nursing Sciences
  12. (2006) Basic Degree in Nursing Sciences
  13. (2004) Mbbs
  14. (2004) Basic Degree in Nursing Sciences
  15. (2003) Basic Degree in Nursing Sciences
  16. (2002) Mbbs
  17. (2002) Basec Degree in Nursing Sciences
  18. (2001) Mbbs
  19. (2001) Basic Degree in Nursing Sciences
  20. (2000) Basic Degree in Nursing Sciences
  21. (2000) Mbbs
Others
  1. (2008) ADNS - Advanced Diploma in Nursing (Oncology)
  2. (2006) ADNS - Advanced Diploma in Nursing (Oncology)
  3. (2004) ADNS - Advanced Diploma in Nursing (Oncology)
  4. (2003) Advanced Diploma in Nursing (Oncology)
  5. (2004) Diploma in Radiography
  6. (2003) Diploma in Radiography
  7. (2002) Diploma in Radiography
  8. (2001) Diploma in Radiography
  9. (2000) Diploma in Radiography

PATENT/IPR

  • Master of Clinical Oncology Programme Syllabus
    literary work (University)

SOCIAL RESPONSIBILITY ACTIVITIES

  • Organiser of Iaea Ras6086 Regional Training Course On Multimodality Treatment in Palliative Radiotherapy, (22 Mar 2021 - 25 Feb 2021)
  • Searog Council Advisor, (01 Jan 2019 - 31 Dec 2019)
  • Faro Council Member Representing Malaysian Oncological Society and Malaysia, (01 Jan 2019 - 31 Dec 2019)
  • Breast Cancer Public Forum, (18 Oct 2014 - 18 Oct 2014)
  • Smk Seksyen 9 Shah Alam Niners a+ Committee Member, (01 Jul 2013 - 12 Oct 2013)
  • Women's Integration Society, (01 Jan 2002)